Waldemar Priebe - Cns Pharmaceuticals Founder

All Insiders . USA . 
Stock . Cns Pharmaceuticals . Stakeholders . Insider . Waldemar Priebe
CNSP Stock  USD 3.71  0.09  2.49%   

Insider

Waldemar Priebe is Founder of Cns Pharmaceuticals
Address 2100 West Loop South, Houston, TX, United States, 77027
Phone800 946 9185
Webhttps://www.cnspharma.com

Latest Insider Transactions

2023-03-27Disposed of 2 shares @ 2725View
2023-03-24Disposed of 2 shares @ 2700View
2023-03-22Disposed of 2 shares @ 2700View
2023-03-20Disposed of 2 shares @ 2700View
2023-03-17Disposed of 2 shares @ 2825View
2023-03-15Disposed of 2 shares @ 3050View
2023-03-13Disposed of 2 shares @ 3250View
2023-03-10Disposed of 2 shares @ 3225View

Waldemar Priebe Latest Insider Activity

Tracking and analyzing the buying and selling activities of Waldemar Priebe against Cns Pharmaceuticals stock is an integral part of due diligence when investing in Cns Pharmaceuticals. Waldemar Priebe insider activity provides valuable insight into whether Cns Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Cns Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cns Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
 
Waldemar Priebe over a year ago
Sale by Waldemar Priebe of 5500 shares of Cns Pharmaceuticals

Cns Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (2.24) % which means that it has lost $2.24 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.1878) %, meaning that it created substantial loss on money invested by shareholders. Cns Pharmaceuticals' management efficiency ratios could be used to measure how well Cns Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/22/2025, Return On Capital Employed is likely to grow to 5.14, though Return On Tangible Assets are likely to grow to (12.11). As of 03/22/2025, Total Current Liabilities is likely to grow to about 7.4 M, while Liabilities And Stockholders Equity is likely to drop slightly above 1.9 M.
Cns Pharmaceuticals currently holds 300.81 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Cns Pharmaceuticals has a current ratio of 12.09, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Cns Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Peter FacchiniEnveric Biosciences
61
Susan DexterSonnet Biotherapeutics Holdings
70
LaBella MSZyVersa Therapeutics
66
Todd MDHepion Pharmaceuticals
55
Joseph FerraElevation Oncology
50
RPh PharmDElevation Oncology
40
Daren UreHepion Pharmaceuticals
N/A
Pablo MDZyVersa Therapeutics
N/A
BSc BScHepion Pharmaceuticals
66
Gabriel BAImmix Biopharma
38
MBA MDImmix Biopharma
49
JD MBAImmix Biopharma
N/A
Nandan BSImmix Biopharma
63
Ibrahim MDEnveric Biosciences
55
Stephen MDHepion Pharmaceuticals
N/A
Launa AspesletHepion Pharmaceuticals
N/A
Brian SullivanElevation Oncology
N/A
Avani KanubaddiEnveric Biosciences
51
John CiniSonnet Biotherapeutics Holdings
72
Joseph TuckerEnveric Biosciences
56
MBA IVEnveric Biosciences
68
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company was incorporated in 2017 and is based in Houston, Texas. Cns Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people. Cns Pharmaceuticals (CNSP) is traded on NASDAQ Exchange in USA. It is located in 2100 West Loop South, Houston, TX, United States, 77027 and employs 3 people. Cns Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Return On Equity-10.19
Return On Asset-2.24

Cns Pharmaceuticals Leadership Team

Elected by the shareholders, the Cns Pharmaceuticals' board of directors comprises two types of representatives: Cns Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cns. The board's role is to monitor Cns Pharmaceuticals' management team and ensure that shareholders' interests are well served. Cns Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cns Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
JD Esq, President CEO
Waldemar Priebe, Founder
Donald Picker, Chief Officer
CPA CTP, Chief Officer

Cns Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cns Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-10.19
Return On Asset-2.24
Current Valuation(1.27 M)
Shares Outstanding40.75 M
Shares Owned By Insiders1.20 %
Shares Owned By Institutions0.70 %
Number Of Shares Shorted3.93 M
Price To Earning(13.70) X
Price To Book1.69 X
EBITDA(18.86 M)

Pair Trading with Cns Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Cns Stock

  0.64CDIOW Cardio DiagnosticsPairCorr
  0.68VINC Vincerx Pharma Earnings Call This WeekPairCorr
  0.65ELEV Elevation OncologyPairCorr
  0.7ELVN Enliven TherapeuticsPairCorr

Moving against Cns Stock

  0.86GILD Gilead SciencesPairCorr
  0.8AZN AstraZeneca PLC ADRPairCorr
  0.76SNY Sanofi ADRPairCorr
  0.71OCX OncoCyte CorpPairCorr
  0.68BMY Bristol Myers SquibbPairCorr
The ability to find closely correlated positions to Cns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cns Pharmaceuticals to buy it.
The correlation of Cns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Cns Stock Analysis

When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY